A股異動 | 前沿生物-U漲近6% 與魚躍醫療擬在生命科學領域進一步開展藥械合作
格隆匯12月9日丨前沿生物-U漲近6%,報18.4元,總市值69億元。前沿生物公佈,2022年12月7日,前沿生物藥業(南京)股份有限公司與江蘇魚躍醫療設備股份有限公司達成戰略合作並簽署《戰略合作協議》,雙方就公司在研新藥霧化吸入用FB2001在臨牀試驗階段所需的霧化吸入裝置的供應、服務保障,以及雙方在生命科學領域進一步開展藥械合作等事宜,達成戰略合作意向。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.